Precigen Inc (PGEN)

$6.75 +0.20 (3.05%)
Market Cap 2.34B
Revenue (ttm) 9.68M
Net Income (ttm) -250.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 24.40
Profit Margin -2,589.26%
Debt to Equity Ratio 2.15
Volume 4,356,000
Avg Vol 5,300,082
Day's Range N/A - N/A
Shares Out 356.51M
Stochastic %K 54%
Beta 1.02
Analysts Strong Sell
Price Target $14.50

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell t...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 556 9900
Address:
20374 Seneca Meadows Parkway, Germantown, United States
Golfer109
Golfer109 Aug. 19 at 11:25 AM
$PGEN moderna stock went up today 50% on their cancer vaccine. We already have those things coming in. If our head and neck comes in that area the stock could be over 100
0 · Reply
dsup
dsup Aug. 18 at 9:34 PM
$PGEN
0 · Reply
Avoc
Avoc Aug. 18 at 8:10 PM
$PGEN After a quick swing in LUNR I'm back in PGEN with 30K shares @ $6,78.
0 · Reply
yjsw
yjsw Aug. 18 at 7:43 PM
$PGEN Jason Bulter at Citizens JMP has not issued any note / comments / update on PGEN after Q2 2026 earnings release on August 4, 2026. His last rating on PGEN is still "buy" with a price target $11 issued on May 14, 2026. He attended the Q2 2026 earnings call and asked several detailed questions. Certainly Q2 2026 results of PGEN far exceed his estimates as well as all other analysts. Isn't this intriguing?
0 · Reply
ACCool
ACCool Aug. 18 at 4:41 PM
$PGEN
0 · Reply
zackplanet42
zackplanet42 Aug. 18 at 3:12 PM
$PGEN Flapping in the wind on pretty low volume this morning. low conviction. XBI is down. Every major index is down. Max pain sitting at 5.00 for Friday expiry. My take: Overall market action is driving a few sellers, but most are simply holding and waiting. Not a bad average up opportunity, otherwise I'm not seeing anything actionable.
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Aug. 18 at 12:55 PM
$PGEN pretty volatile pre market session. Should be interesting on the open.
0 · Reply
biscko11
biscko11 Aug. 17 at 6:34 PM
$PGEN huge 7.50 options expires on 8/21 this week should be interesting week. I'm betting it stays under until next week.
0 · Reply
RaphaelRapoport
RaphaelRapoport Aug. 17 at 2:49 PM
$PGEN
0 · Reply
Doggissimo
Doggissimo Aug. 17 at 2:49 PM
$PGEN This action is wild. itll be just under the option price 8/24 then probably rips from there
0 · Reply
Latest News on PGEN
Precigen price target raised to $18 from $14 at H.C. Wainwright

2026-08-05T10:06:11.000Z - 14 days ago

Precigen price target raised to $18 from $14 at H.C. Wainwright

Precigen Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Precigen Earnings Call Transcript: Q2 2026

Precigen Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Precigen Earnings release: Q2 2026

Precigen Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Precigen Quarterly report: Q2 2026

Precigen reports Q2 EPS 5c vs., (9c) last year

2026-08-04T20:28:35.000Z - 14 days ago

Precigen reports Q2 EPS 5c vs., (9c) last year

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

Aug 4, 2026, 4:01 PM EDT - 14 days ago

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Precigen Transcript: AGM 2026

Jun 18, 2026, 9:00 AM EDT - 2 months ago

Precigen Transcript: AGM 2026

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Jun 15, 2026, 6:40 AM EDT - 2 months ago

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:20 AM EDT - 2 months ago

Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Precigen presents long-term follow-up data from study of Papzimeos

2026-05-31T21:35:05.000Z - 2 months ago

Precigen presents long-term follow-up data from study of Papzimeos

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

May 30, 2026, 2:30 PM EDT - 2 months ago

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen price target raised to $14 from $11 at H.C. Wainwright

2026-05-28T10:13:45.000Z - 2 months ago

Precigen price target raised to $14 from $11 at H.C. Wainwright

Precigen receives orphan drug exclusivity for papzimeos in the U.S.

2026-05-27T11:17:06.000Z - 3 months ago

Precigen receives orphan drug exclusivity for papzimeos in the U.S.

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

May 27, 2026, 7:00 AM EDT - 3 months ago

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026, 8:05 AM EDT - 3 months ago

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

Precigen price target raised to $11 from $10 at H.C. Wainwright

2026-05-14T10:22:58.000Z - 3 months ago

Precigen price target raised to $11 from $10 at H.C. Wainwright

Precigen price target raised to $11 from $9 at Citizens

2026-05-14T09:56:27.000Z - 3 months ago

Precigen price target raised to $11 from $9 at Citizens

Precigen reports Q1 EPS (2c) vs. (18c) last year

2026-05-13T21:07:28.000Z - 3 months ago

Precigen reports Q1 EPS (2c) vs. (18c) last year

Precigen Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Precigen Earnings Call Transcript: Q1 2026

Precigen Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Precigen Earnings release: Q1 2026

Precigen Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Precigen Quarterly report: Q1 2026

Precigen Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026, 4:05 PM EDT - 3 months ago

Precigen Reports First Quarter 2026 Financial Results and Business Updates

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

May 7, 2026, 4:05 PM EDT - 3 months ago

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

Precigen Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Precigen Proxy statement: Proxy filing

Precigen Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Precigen Proxy statement: Proxy filing

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M

2026-04-07T12:02:54.000Z - 4 months ago

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

2026-04-07T11:17:44.000Z - 4 months ago

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Apr 7, 2026, 7:00 AM EDT - 4 months ago

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Precigen Transcript: Fireside chat

Mar 31, 2026, 11:00 AM EDT - 5 months ago

Precigen Transcript: Fireside chat

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

Precigen jumps on Q1 outlook despite earnings miss

2026-03-26T15:25:13.000Z - 5 months ago

Precigen jumps on Q1 outlook despite earnings miss

Precigen price target raised to $10 from $9 at H.C. Wainwright

2026-03-26T10:10:56.000Z - 5 months ago

Precigen price target raised to $10 from $9 at H.C. Wainwright

Precigen price target raised to $9 from $8 at Citizens

2026-03-26T10:00:46.000Z - 5 months ago

Precigen price target raised to $9 from $8 at Citizens

Precigen Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Precigen Earnings Call Transcript: Q4 2025

Precigen Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Precigen Annual report: Q4 2025

Precigen Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Precigen Earnings release: Q4 2025

Precigen Reports Full Year 2025 Financial Results and Business Updates

Mar 25, 2026, 4:05 PM EDT - 5 months ago

Precigen Reports Full Year 2025 Financial Results and Business Updates

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

Mar 11, 2026, 4:05 PM EDT - 5 months ago

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Jan 20, 2026, 8:05 AM EST - 7 months ago

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 10:30 AM EST - 7 months ago

Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Precigen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 10:30 AM EST - 7 months ago

Precigen Slides: 44th Annual J.P. Morgan Healthcare Conference

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 7 months ago

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 8 months ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

JPMorgan healthcare analysts hold an analyst/industry conference call

2025-12-03T15:00:13.000Z - 9 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

2025-11-14T11:16:04.000Z - 9 months ago

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

Precigen Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Precigen Earnings Call Transcript: Q3 2025

Precigen Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Precigen Quarterly report: Q3 2025

Precigen Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Precigen Earnings release: Q3 2025

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 4:05 PM EST - 9 months ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Nov 6, 2025, 4:30 PM EST - 10 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Oct 13, 2025, 7:00 AM EDT - 11 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Precigen Transcript: Fireside Chat

Sep 2, 2025, 11:00 AM EDT - 1 year ago

Precigen Transcript: Fireside Chat

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Aug 25, 2025, 8:05 AM EDT - 1 year ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Precigen Registration statement: Registration Filing

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Precigen Registration statement: Registration Filing

Precigen Transcript: Investor Update

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Precigen Transcript: Investor Update

Precigen Press release: Investor Update

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Precigen Press release: Investor Update

Precigen Slides: Investor Update

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Precigen Slides: Investor Update

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:18 AM EDT - 1 year ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 15, 2025, 7:00 AM EDT - 1 year ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Precigen Quarterly report: Q2 2025

Precigen Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

Precigen Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

Precigen Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Precigen Quarterly report: Q1 2025

Precigen Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Precigen Earnings release: Q1 2025

Precigen Proxy statement: Proxy Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Apr 16, 2025, 8:05 AM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Precigen Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q4 2024

Precigen Annual report: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Annual report: Q4 2024

Precigen Earnings release: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings release: Q4 2024

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Feb 25, 2025, 8:05 AM EST - 1 year ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Precigen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 12:00 PM EST - 1 year ago

Precigen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Precigen Transcript: Stifel 2024 Healthcare Conference

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Precigen Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Precigen Quarterly report: Q3 2024

Precigen Earnings release: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Precigen Earnings release: Q3 2024

Precigen to Participate in the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 2 years ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Precigen Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q2 2024

Precigen Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Quarterly report: Q2 2024

Precigen Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings release: Q2 2024

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 7, 2024, 9:30 PM EDT - 2 years ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 2 years ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 2 years ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Transcript: Study Result

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Transcript: Study Result

Precigen Press release: Study Result

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Press release: Study Result

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Jun 3, 2024, 9:30 AM EDT - 2 years ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen Proxy statement: Proxy Filing

May 28, 2024, 8:00 AM EDT - 2 years ago

Precigen Proxy statement: Proxy Filing

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 2 years ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Precigen Quarterly report: Q1 2024

Precigen Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Precigen Earnings release: Q1 2024

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

May 8, 2024, 4:05 PM EDT - 2 years ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 2 years ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 2 years ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q4 2023

Precigen Annual report: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Annual report: Q4 2023

Precigen Earnings release: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings release: Q4 2023

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Golfer109
Golfer109 Aug. 19 at 11:25 AM
$PGEN moderna stock went up today 50% on their cancer vaccine. We already have those things coming in. If our head and neck comes in that area the stock could be over 100
0 · Reply
dsup
dsup Aug. 18 at 9:34 PM
$PGEN
0 · Reply
Avoc
Avoc Aug. 18 at 8:10 PM
$PGEN After a quick swing in LUNR I'm back in PGEN with 30K shares @ $6,78.
0 · Reply
yjsw
yjsw Aug. 18 at 7:43 PM
$PGEN Jason Bulter at Citizens JMP has not issued any note / comments / update on PGEN after Q2 2026 earnings release on August 4, 2026. His last rating on PGEN is still "buy" with a price target $11 issued on May 14, 2026. He attended the Q2 2026 earnings call and asked several detailed questions. Certainly Q2 2026 results of PGEN far exceed his estimates as well as all other analysts. Isn't this intriguing?
0 · Reply
ACCool
ACCool Aug. 18 at 4:41 PM
$PGEN
0 · Reply
zackplanet42
zackplanet42 Aug. 18 at 3:12 PM
$PGEN Flapping in the wind on pretty low volume this morning. low conviction. XBI is down. Every major index is down. Max pain sitting at 5.00 for Friday expiry. My take: Overall market action is driving a few sellers, but most are simply holding and waiting. Not a bad average up opportunity, otherwise I'm not seeing anything actionable.
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Aug. 18 at 12:55 PM
$PGEN pretty volatile pre market session. Should be interesting on the open.
0 · Reply
biscko11
biscko11 Aug. 17 at 6:34 PM
$PGEN huge 7.50 options expires on 8/21 this week should be interesting week. I'm betting it stays under until next week.
0 · Reply
RaphaelRapoport
RaphaelRapoport Aug. 17 at 2:49 PM
$PGEN
0 · Reply
Doggissimo
Doggissimo Aug. 17 at 2:49 PM
$PGEN This action is wild. itll be just under the option price 8/24 then probably rips from there
0 · Reply
dsup
dsup Aug. 15 at 4:12 AM
$PGEN i bet she rips 8/24
1 · Reply
Jrtreats
Jrtreats Aug. 14 at 8:01 PM
$PGEN I think the market is starting to price in INO-3107 being approved. I personally hope pgen goes too $15. All better for my investment. I do think the market is big enough for both for a while until one takes the preferedcare role.
3 · Reply
StockDad0927
StockDad0927 Aug. 14 at 6:52 PM
$PGEN 🖕🏻
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Aug. 14 at 2:43 PM
$PGEN long term very bullish, but gonna sell a chunk of my position and look to get back in at a lower price point. I’ve seen this tank irrationally too many times. Gonna lock in some gains and let the shorts do their thing and crush this to below $5.
2 · Reply
WenABVEAudit
WenABVEAudit Aug. 14 at 1:56 PM
$PGEN out at 6.30 from 3.37 . 250 shares
0 · Reply
FlyontheCEOSwall
FlyontheCEOSwall Aug. 14 at 1:55 PM
$PGEN xbi killing biotech again.
0 · Reply
longshort777
longshort777 Aug. 14 at 12:49 AM
$PGEN this is a fantastic buy right here
0 · Reply
M22
M22 Aug. 13 at 11:59 PM
$PGEN
0 · Reply
Jrtreats
Jrtreats Aug. 13 at 11:13 PM
$PGEN I almost bought some of this stock at $4. I wish I had. I would sell it now and buy 7 shares of INO for every pgen I sold. Then let INO run. It going alot higher than the $7 buck range.
1 · Reply
Tlinz50
Tlinz50 Aug. 13 at 7:42 PM
$PGEN Potential catalyst Before EOY EU EMP approval. I believe Helen said before there more potential patients in the EU than in the US.
0 · Reply
blue_horseshoe_9P
blue_horseshoe_9P Aug. 13 at 7:30 PM
$PGEN Shorts know the company does not give guidance outside of earnings calls. The only potential catalysts will be increased price targets or new analysts initiating coverage to get more exposure to new investors. Absent of that, shorts will be able to play their games for the next couple months and get their scraps.
1 · Reply
Wacousta
Wacousta Aug. 13 at 6:36 PM
$PGEN FYI https://x.com/PatientCM/status/2087909542487372261/video/1
1 · Reply